Literature DB >> 16269323

Ceruloplasmin in neurodegenerative diseases.

Vadim Vassiliev1, Zena Leah Harris, Paolo Zatta.   

Abstract

For decades, abnormalities in ceruloplasmin (Cp) synthesis have been associated with neurodegenerative disease. From the early observation that low circulating serum ceruloplasmin levels served as a marker for Wilson's disease to the recent characterization of a neurodegenerative disorder associated with a complete lack of serum ceruloplasmin, the link between Cp and neuropathology has strengthened. The mechanisms associated with these different central nervous system abnormalities are very distinct. In Wilson's disease, a defect in the P-type ATPase results in abnormal hepatic copper accumulation that eventually leaks into the circulation and is abnormally deposited in the brain. In this case, copper deposition results in the neurodegenerative phenotype observed. Patients with autosomal recessive condition, aceruloplasminemia, lack the ferroxidase activity inherent to the multi-copper oxidase ceruloplasmin and develop abnormal iron accumulation within the central nervous system. In the following review ceruloplasmin gene expression, structure and function will be presented and the role of ceruloplasmin in iron metabolism will be discussed. The molecular events underlying the different forms of neurodegeneration observed will be presented. Understanding the role of ceruloplasmin within the central nervous system is fundamental to further our understanding of the pathology observed. Is the ferroxidase function more essential than the antioxidant role? Does Cp help maintain nitrosothiol stores or does it oxidize critical brain substrates? The answers to these questions hold the promise for the treatment of devastating neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. It is essential to further elucidate the mechanism of the neuronal injury associated with these disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16269323     DOI: 10.1016/j.brainresrev.2005.03.003

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  31 in total

1.  Does ceruloplasmin differential express in the brain of Ts65Dn: a mouse mode of Down syndrome?

Authors:  Bin Yu; Jing Kong; Baoling Xing; Ziqiang Zhu; Bin Zhang; Qiu-Wei Wang; Shi-He Shao
Journal:  Neurol Sci       Date:  2013-11-17       Impact factor: 3.307

2.  Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson's disease.

Authors:  Na Zhao; Jianqiu Xiao; Zhiyong Zheng; Guoqiang Fei; Feng Zhang; Lirong Jin; Chunjiu Zhong
Journal:  Neurosci Bull       Date:  2015-03-10       Impact factor: 5.203

3.  Neuroprotective role of lipoic acid against acute toxicity of N-acetylaspartic acid.

Authors:  Carolina Didonet Pederzolli; Andrea Pereira Rosa; Amanda Szekir de Oliveira; Juliana G Coelho; Débora da Luz Becker; Giovana Reche Dalazen; Tarsila Barros Moraes; Carlos S Dutra-Filho
Journal:  Mol Cell Biochem       Date:  2010-08-05       Impact factor: 3.396

4.  Protective role of macrophage-derived ceruloplasmin in inflammatory bowel disease.

Authors:  Bakytzhan Bakhautdin; Maria Febbraio; Esen Goksoy; Carol A de la Motte; Muhammet F Gulen; Erin Patricia Childers; Stanley L Hazen; Xiaoxia Li; Paul L Fox
Journal:  Gut       Date:  2012-02-16       Impact factor: 23.059

5.  Brain Ceruloplasmin Expression After Experimental Intracerebral Hemorrhage and Protection Against Iron-Induced Brain Injury.

Authors:  Hongwei Liu; Ya Hua; Richard F Keep; Guohua Xi
Journal:  Transl Stroke Res       Date:  2018-10-12       Impact factor: 6.829

Review 6.  Ceruloplasmin and what it might do.

Authors:  J Healy; K Tipton
Journal:  J Neural Transm (Vienna)       Date:  2007-04-04       Impact factor: 3.575

7.  Elevated serum brain natriuretic peptide and matrix metalloproteinases 2 and 9 in Wilson's disease.

Authors:  Nan Cheng; Honghao Wang; Jianjian Dong; Suyue Pan; Xun Wang; Yongsheng Han; Yongzhu Han; Renmin Yang
Journal:  Metab Brain Dis       Date:  2015-06-17       Impact factor: 3.584

8.  Renal impairment in different phenotypes of Wilson disease.

Authors:  Honghao Wang; Zhihua Zhou; Jiyuan Hu; Yongzhu Han; Xun Wang; Nan Cheng; Yunfan Wu; Renmin Yang
Journal:  Neurol Sci       Date:  2015-07-29       Impact factor: 3.307

Review 9.  Iron in chronic brain disorders: imaging and neurotherapeutic implications.

Authors:  James Stankiewicz; S Scott Panter; Mohit Neema; Ashish Arora; Courtney E Batt; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

10.  Ceruloplasmin has two nearly identical sites that bind myeloperoxidase.

Authors:  Bakytzhan Bakhautdin; Esen Goksoy Bakhautdin; Paul L Fox
Journal:  Biochem Biophys Res Commun       Date:  2014-10-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.